Isn't this similar to the changes made in the Rem. trials? A change from # of deaths/ventilator to just looking at the time it takes to get better for some patients? I would think a change like this at this point shows the data they are looking at does not show fewer deaths or patients needing ventilator.

The fact that the DSMC advised no changes and cytodyn has not requested any changes in our trial means a lot. It looks like other drugs are trying hard to show efficacy in some way. Leronlimab really is looking like not just the best drug but possible the only drug that works.